Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-04
2006-07-04
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252110, C514S252120, C514S235800, C514S306000, C514S362000, C514S363000, C514S249000, C544S129000, C544S349000, C544S353000, C544S354000, C544S357000, C546S084000, C546S277400, C548S134000, C548S452000, C548S469000, C548S511000, C548S503000, C549S398000, C549S399000
Reexamination Certificate
active
07071180
ABSTRACT:
The invention relates to compounds of the general formula (I):whereinAr is optionally substituted aryl or heteroaryl;A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members;B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—;R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl;R1is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)];R2a, R3a, R4, R5, R6and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof.The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).
REFERENCES:
patent: 3253989 (1966-05-01), Moser et al.
patent: 6465467 (2002-10-01), Nilsson et al.
patent: 583715 (1997-01-01), None
patent: 2433397 (1997-01-01), None
patent: 0572863 (1993-12-01), None
patent: 0655440 (1995-05-01), None
patent: 0657426 (1995-06-01), None
patent: 0711757 (1996-05-01), None
patent: 0863136 (1998-09-01), None
patent: 1440722 (1976-06-01), None
patent: 1457005 (1976-12-01), None
patent: 1465946 (1977-03-01), None
patent: WO9501976 (1995-01-01), None
patent: WO9602525 (1996-02-01), None
patent: WO9611930 (1996-04-01), None
patent: WO97/14689 (1997-04-01), None
patent: WO9842692 (1998-10-01), None
patent: WO9903833 (1999-01-01), None
patent: WO9958490 (1999-11-01), None
patent: WO0012475 (2000-03-01), None
patent: WO0012482 (2000-03-01), None
patent: WO0012502 (2000-03-01), None
patent: WO0012510 (2000-03-01), None
Lumma, W.C. Jr et al., J. of Med. Chem., vol. 21, No. 6 (1978) pp. 536-542.
Rano et al.,Tetrahedron Letters, vol. 36, No. 22 (1995) pp. 3789-3792.
Hori et al., Chem. Pharm. Bull., vol. 41, No. 10, (1993) pp. 1832=1841.
Lumma et al., J. of Med. Chem., vol. 24, (1981) pp. 93-101.
Jenck et al., Opin. Invest. Drugs, vol. 7, No. 10 (1998) pp. 1587.
G.A., Kennett, IDrugs, vol. 1, No. 4, (1998) pp. 456-470.
Sargent, P.A. et al.,Psychopharmacology, vol. 133 (1997) pp. 309-312.
Tecott, L.H. et al.,Nature, vol. 374 (1995) pp: 542-546.
Dourish, Colin, Obesity Research, vol. 3, No. 4 (1995) pp. 449-462.
Leysen, Dirk C.M.,IDrugs, vol. 2, No. 2 (1999) pp. 109-120.
Dictionary of Drugs, Chemical Data, Structures and Bibliographies, Chapman and Hall, pp. 504, 972,1158 (1990).
Obata et al., PubMed Abstract 12591127, also cited as Brain Res., 965/1-2, 114-20 (2003).
Volgin et al., PubMed Abstract 12670306, also cited as Eur. J. Neurosci. 17/6, 1179-88 (2003).
Hietala et al., PubMed 11594443, also cited as Psychopharmacology (Berl). 157/2, 180-7 (2001).
Lane RM, PubMed Abstract 9097897, also cited as Psychopharmacol. 11/1, 72-82 (1997).
Jönsson Mattias
Nilsson Björn
Nilsson Jonas
Pelcman Benjamin
Ringberg Erik
Biovitrum AB
Patel Sudhaker B.
Raymond Richard L.
LandOfFree
Certain arylaliphatic and heteroaryl-aliphatic piperazinyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain arylaliphatic and heteroaryl-aliphatic piperazinyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain arylaliphatic and heteroaryl-aliphatic piperazinyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3563282